 The FDA has lifted the clinical hold on AIM ImmunoTech Incs NYSE: AIM investigational new drug IND application for a Phase 2 study of Ampligen for locally advanced pancreatic cancer AMP-270. The AMP-270 clinical trials primary objective compares the efficacy of. 